Sign up for our FREE E-Weekly for more coverage like this sent to your inbox!
Earlier this months, the company suspended clinical trials of the drug BMS-986094, citing “the emergence of a serious safety issue.” Until now, officials have stayed mum on the exact risk posed to patients.
In addition to the participant who died, eight others were hospitalized due to adverse reactions to the drug. Bristol-Myers is investigating what caused the hospitalizations, though heart and kidney toxicity could be a factor.
More Articles on Patient Safety:
Kansas Healthcare Providers Partner for Infection Prevention Education
Loyola University Receives Grant for Infection Prevention Education
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.